TiumBio Co. Ltd
TiumBio Co., Ltd., a drug discovery company, researches and develops therapeutics for patients with unaddressed rare diseases. The company's products pipeline includes chemical entity-based drugs and biopharmaceuticals comprising NCE401, NCE403, NCE406, and NBP604. It has a collaboration agreement with Oncodesign Société Anonyme for the research and development of fibrosis drug candidates. The co… Read more
TiumBio Co. Ltd (321550) - Total Liabilities
Latest total liabilities as of September 2025: ₩67.60 Billion KRW
Based on the latest financial reports, TiumBio Co. Ltd (321550) has total liabilities worth ₩67.60 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
TiumBio Co. Ltd - Total Liabilities Trend (2017–2024)
This chart illustrates how TiumBio Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
TiumBio Co. Ltd Competitors by Total Liabilities
The table below lists competitors of TiumBio Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Fineotex Chemical Limited
NSE:FCL
|
India | ₹898.43 Million |
|
Shenzhen L&A Design Holding Limited
SHE:300949
|
China | CN¥578.16 Million |
|
Barton Gold Holdings Ltd
AU:BGD
|
Australia | AU$14.80 Million |
|
Gamehost Inc
PINK:GHIFF
|
USA | $60.50 Million |
|
Circus SE
XETRA:CA1
|
Germany | €16.62 Million |
|
CH Biotech R&D Co., Ltd.
TW:6534
|
Taiwan | NT$1.06 Billion |
|
Gentas Genel Metal Sanayi ve Ticaret AS
IS:GENTS
|
Turkey | TL1.89 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down TiumBio Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.35 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.75 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.65 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how TiumBio Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for TiumBio Co. Ltd (2017–2024)
The table below shows the annual total liabilities of TiumBio Co. Ltd from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩54.83 Billion | +11.50% |
| 2023-12-31 | ₩49.17 Billion | +39.61% |
| 2022-12-31 | ₩35.22 Billion | +20.78% |
| 2021-12-31 | ₩29.16 Billion | +925.12% |
| 2020-12-31 | ₩2.84 Billion | +196.86% |
| 2019-12-31 | ₩958.28 Million | +66.72% |
| 2018-12-31 | ₩574.77 Million | -96.66% |
| 2017-12-31 | ₩17.21 Billion | -- |